# GO / NO-GO DECISION REPORT

## DIU AI-Assisted Triage & Treatment Challenge (PROJ00628)
### Prepared for: Veteran Vectors (Prime) | Authentic Consortium
### Date: February 24, 2026

---

## 1. OPPORTUNITY SUMMARY

| Field | Detail |
|---|---|
| **Solicitation** | DIU CSO HQ0845-20-S-C001 -- Area of Interest: AI-Assisted Triage & Treatment |
| **Project ID** | PROJ00628 |
| **Sponsor** | DIU + PM Soldier Medical Devices (PEO Soldier) + 30th Medical Brigade |
| **Award Type** | Prize Challenge (up to 8 finalists); pathway to OTA Prototype Agreement |
| **Prize Pool** | $999,000 (split among finalists) |
| **Open Call Close** | March 2, 2026 |
| **Semi-Finalist Notification** | ~March 9, 2026 |
| **Pitch Days** | April 7-8, 2026 |
| **Live Demo (Sword 2026)** | May 8-12, 2026 |
| **Deliverable Scale** | 30 units by May 2026; 15,000 units/yr by May 2027 |

---

## 2. REQUIREMENT FIT ANALYSIS

### 2.1 Core Need
The DoD requires a **portable, ruggedized, network-capable hemodynamic status monitoring system** for forward (Role 1/2) combat medics performing Tactical Combat Casualty Care (TCCC), CASEVAC, and MEDEVAC operations. The system must operate in Disconnected, Intermittent, and Limited-bandwidth (DDIL) environments.

### 2.2 Capability Alignment Matrix

| Requirement | Consortium Capability | Fit |
|---|---|---|
| Hemodynamic monitoring (vitals, trend analytics) | Software/AI analytics layer -- Veteran Vectors core competency in AI/ML | STRONG |
| Hardware (ruggedized, wearable/standoff, 72hr battery) | Requires hardware partner within consortium (medical device OEM) | MODERATE -- requires partner validation |
| BATDOK / ATAK / EHR integration | Software integration -- achievable via standard APIs and military data standards | STRONG |
| Cloud + on-premise / DDIL edge compute | Edge AI deployment is Veteran Vectors' strength | STRONG |
| FDA 510(k) clearance | Must leverage consortium partner with existing 510(k) pathway or predicate device | CRITICAL GAP if no partner identified |
| IL-5 ATO / FedRAMP | Consortium experience with gov cloud compliance | MODERATE -- timeline-dependent |
| Manufacturing scale (15k units/yr) | Requires manufacturing consortium partner | MODERATE -- requires partner validation |
| AI-assisted triage decision support | Core alignment with Veteran Vectors AI/ML capabilities | STRONG |

### 2.3 Consortium Strengths
- **Veteran Vectors (Prime):** Veteran-owned small business; AI/ML software development; edge computing; DoD-cleared personnel; mission-driven culture with firsthand understanding of battlefield conditions
- **Authentic Consortium Partners (Potential Roles):**
  - Medical device OEM partner (hardware, FDA 510(k))
  - Cloud/cybersecurity partner (IL-5, FedRAMP)
  - Manufacturing/logistics partner (scale production)
  - Clinical/TCCC subject matter experts

---

## 3. RISK ASSESSMENT

### 3.1 Key Risks

| Risk | Severity | Likelihood | Mitigation |
|---|---|---|---|
| **No FDA 510(k) predicate device in consortium** | HIGH | MEDIUM | Identify and onboard medical device partner with existing clearance pathway immediately |
| **Tight timeline (30 units by May 2026)** | HIGH | MEDIUM | Use COTS hardware base with custom AI software layer; minimize custom HW |
| **Hardware ruggedization requirements** | MEDIUM | LOW | Partner with proven mil-spec device manufacturer |
| **DDIL edge compute performance** | MEDIUM | LOW | Leverage existing edge AI frameworks; prototype early |
| **Manufacturing scale to 15k/yr** | MEDIUM | MEDIUM | Contract manufacturing partner with DoD supply chain experience |
| **Prize-only structure (no guaranteed contract)** | LOW | HIGH | View as pipeline to OTA prototype agreement; limit investment accordingly |
| **Competition from established medical device companies** | MEDIUM | HIGH | Differentiate on AI/ML analytics and software superiority |

### 3.2 Showstoppers
1. **FDA pathway** -- Without a consortium member possessing a 510(k)-cleared hemodynamic monitoring device (or credible predicate device pathway), the proposal will score poorly on System Effectiveness.
2. **Hardware availability** -- 30 functional units by May 2026 requires starting from a COTS platform, not a custom build.

---

## 4. FINANCIAL ANALYSIS

| Item | Estimate |
|---|---|
| **Proposal Development Cost** | $15,000 - $25,000 (labor, prototyping concepts, travel) |
| **Prize Award (if selected)** | Up to ~$125,000 per finalist (8-way split of $999k) |
| **Follow-on OTA Prototype Value** | $2M - $10M (typical DIU prototype OTA range) |
| **Production Contract Potential** | $50M+ (15,000 units x multi-year procurement) |
| **ROI on Bid Investment** | High if consortium is properly assembled; proposal cost is <1% of potential follow-on |

---

## 5. COMPETITIVE POSITIONING

### Advantages
- **Veteran-owned:** SDVOSB status; authentic understanding of combat medic challenges
- **AI/ML differentiation:** Consortium software capabilities exceed most medical device incumbents
- **Agility:** Small business speed vs. large defense primes
- **Consortium model:** Best-of-breed team without single-vendor overhead

### Disadvantages
- Medical device incumbents (Philips, Masimo, Zoll) have existing FDA-cleared platforms
- Hardware development is not a core Veteran Vectors competency
- Prize challenges attract large applicant pools

---

## 6. GO / NO-GO RECOMMENDATION

### **RECOMMENDATION: CONDITIONAL GO**

**Conditions for GO:**
1. **Confirm a medical device consortium partner** with an existing or near-term FDA 510(k) cleared hemodynamic monitoring device (e.g., pulse oximetry, continuous blood pressure, or similar) within **48 hours** (before March 2 deadline)
2. **Confirm a manufacturing partner** capable of delivering 30 prototype units by May 2026
3. **Total bid investment stays under $25,000** given prize-only initial structure

**Rationale:**
The opportunity is strategically valuable. Even if the prize amount is modest, the pathway to a multi-million dollar OTA prototype agreement and subsequent production contract makes this a high-value pipeline opportunity. Veteran Vectors' AI/ML software capabilities are a strong differentiator for the analytics, decision-support, and integration layers. The consortium model allows the team to cover hardware gaps. However, proceeding without a confirmed FDA 510(k) pathway would be a losing proposition.

**If conditions are met: FULL GO -- proceed with Solution Brief and White Paper submission.**
**If conditions are NOT met by Feb 26: NO-GO -- preserve resources for better-aligned opportunities.**

---

*Prepared by: AI Strategy Analysis | Authentic Consortium Bid Team*
